1. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
2. 2) Chi, S., de Vere White, R.W., Muenzer, J.T. and Gumerlock, P.H. (1997). Frequent alteration of CDKN2 (p16ink4A/MTS1) expression in human primary prostate carcinoma. Clin Cancer Res 3, 1889-1897.
3. 3) El-Naggar, A.K., Lai, S., Clayman, G., Lee, J.K.J., Luna, M.A., Goepfert, H. and Batsakis, J.G. (1997). Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous cell carcinoma. Am J patho 151, 1767-1774.
4. 4) Gonzalez-Zulucta, M., Bender, C.M., Yang, A.S., Nguyen, T.D., Beart, R.W. and van Torout, J.M. (1995). Methylation of 5´CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 15, 4531-4535.